Vivo Capital LLC Acquires New Holdings in Regulus Therapeutics Inc. (NASDAQ:RGLS)

Vivo Capital LLC bought a new position in shares of Regulus Therapeutics Inc. (NASDAQ:RGLS - Free Report) in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 5,000,000 shares of the biopharmaceutical company's stock, valued at approximately $14,400,000. Regulus Therapeutics accounts for about 1.1% of Vivo Capital LLC's holdings, making the stock its 21st biggest holding. Vivo Capital LLC owned 7.64% of Regulus Therapeutics as of its most recent SEC filing.

Separately, Victory Capital Management Inc. boosted its position in shares of Regulus Therapeutics by 5.3% during the 3rd quarter. Victory Capital Management Inc. now owns 233,207 shares of the biopharmaceutical company's stock worth $322,000 after purchasing an additional 11,701 shares during the period. 92.38% of the stock is currently owned by hedge funds and other institutional investors.

Regulus Therapeutics Stock Performance

Shares of NASDAQ:RGLS traded up $0.15 on Friday, hitting $2.42. 204,765 shares of the company's stock were exchanged, compared to its average volume of 300,118. Regulus Therapeutics Inc. has a 1-year low of $1.08 and a 1-year high of $3.79. The company has a market capitalization of $158.43 million, a PE ratio of -1.52 and a beta of 1.57. The firm's 50-day moving average is $2.20 and its 200 day moving average is $1.63.

Regulus Therapeutics (NASDAQ:RGLS - Get Free Report) last announced its quarterly earnings results on Thursday, March 21st. The biopharmaceutical company reported ($0.40) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($0.40). On average, analysts anticipate that Regulus Therapeutics Inc. will post -0.52 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research analysts have recently commented on the company. Wells Fargo & Company raised their price target on Regulus Therapeutics from $2.00 to $3.00 and gave the stock an "equal weight" rating in a research report on Wednesday, March 13th. HC Wainwright reissued a "buy" rating and set a $9.00 target price on shares of Regulus Therapeutics in a research note on Monday, March 25th. Leerink Partnrs reaffirmed an "outperform" rating on shares of Regulus Therapeutics in a research report on Monday, March 18th. Canaccord Genuity Group reduced their price target on shares of Regulus Therapeutics from $12.00 to $11.00 and set a "buy" rating on the stock in a research report on Tuesday, March 19th. Finally, SVB Leerink initiated coverage on shares of Regulus Therapeutics in a research note on Monday, March 18th. They issued an "outperform" rating and a $6.00 price objective for the company. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the stock. According to MarketBeat, Regulus Therapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $7.25.

Regulus Therapeutics Profile

Regulus Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.